Effects of human recombinant-interferon β in experimental autoimmune encephalomyelitis in guinea pigs

References

• Arnason BG, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT (1996): Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 18: 125–148.
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Hayes CE, DeLuca HF (1996): 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93: 7861–7864.
   PubMed Web of Science ®Google Scholar
• Fertsch D, Schoenberg DR, Germain RN, Tou JY, Vogel SN (1987): Induction of macrophage Ia antigen expression by rIFN-gamma and down-regulation by IFN-alpha/beta and dexamethasone are mediated by changes in steady-state levels of Ia mRNA. J Immunol 139: 244–249.
   PubMed Web of Science ®Google Scholar
• Hertz F, Deghenghi R (1985): Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 16: 397–403.
   PubMedGoogle Scholar
• IFNβ Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995): Interferon beta-1b in the treatment of multiple sclerosis, final outcome of the randomized controlled trial. Neurology 45: 177–185.
   Google Scholar
• IFNβ Multiple Sclerosis Study Group (1993): Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.
   PubMed Web of Science ®Google Scholar
• Ling PD, Warren MK, Vogel SN (1985): Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 135: 1857–1863.
   PubMed Web of Science ®Google Scholar
• Lowry PW, Sabella C, Koropchak CM, Watson BN, Thackray HM, Abbruzzi GM, Arvin AM (1993): Investigation of the pathogenesis of varicella-zoster virus infection in guinea pigs by using polymerase chain reaction. J Infect Dis 167: 78–83.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS (1996): Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 46: 12–18.
   PubMed Web of Science ®Google Scholar
• Mannering GJ, Deloria LB (1986): The pharmacology and toxicology of the interferons: An overview. Annu Rev Pharmacol Toxicol 26: 455–515.
   PubMed Web of Science ®Google Scholar
• Nepom GT, Erlich H (1991): MHC class-II molecules and autoimmunity. Annu Rev Immunol 9: 493–525.
   PubMed Web of Science ®Google Scholar
• Noronha A, Toscas A, Jensen MA (1993): Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 46: 145–153.
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK, UBC MS/MRI Study Group (1993): IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667.
   PubMed Web of Science ®Google Scholar
• Rubinstein S, Familletti PC, Pestka S (1981): Convenient assay for interferons. J Virol 37: 755–758.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM (1993): In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43: 2080–2087.
   PubMed Web of Science ®Google Scholar
• Smeltz RB, Swanborg RH (1998): Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease. J Neurosci Res 51: 147–153.
   PubMed Web of Science ®Google Scholar
• Sobel RA, Mitchell ME, Fondren G (1990): Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 136: 1309–1316.
   PubMed Web of Science ®Google Scholar
• Swanborg RH, Swierkosz JE, Saieg RG (1974): Studies on the species-variability of experimental allergic encephalomyelitis in guinea pigs and rats. J Immunol 112: 594–600.
   PubMed Web of Science ®Google Scholar
• Swanborg RH (1995): Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 77: 4–13.
   PubMedGoogle Scholar
• Traugott U, Lebon P (1988): Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann Neurol 24: 243–251.
   PubMed Web of Science ®Google Scholar
• Traugott U, Scheinberg LC, Raine CS (1985): On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol 8: 1–14.
   PubMed Web of Science ®Google Scholar
• Wakabayashi G, Cannon JG, Gelfand JA, Clark BD, Aiura K, Burke JF, Wolff SM, Dinarello CA (1994): Altered interleukin-1 and tumor necrosis factor production and secretion during pyrogenic tolerance to LPS in rabbits. Am J Physiol 267: R329–336.
   Google Scholar
• Yong VW, Chabot S, Stuve O, Williams G (1998): Interferon beta in the treatment of multiple sclerosis: Mechanisms of action. Neurology 51: 682–689.
   PubMed Web of Science ®Google Scholar
• Yu M, Nishiyama A, Trapp BD, Tuohy VK (1996): Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 64: 91–100.
   PubMed Web of Science ®Google Scholar
• van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, Dijkstra CD (1998): Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 84: 14–23.
   PubMed Web of Science ®Google Scholar